IP Verse

Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer - EP3725810B1

PatentPatent Analysis

EP3725810

ASTELLAS PHARMA
Application Number
EP20163993A
Filing Date
May 21, 2013
Status
Revoked
Jan 3, 2025
Grant Date
Jul 6, 2022
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3791896B1
EP3318259B1
EP3725778B1

Bibliography

The patent EP3725810B1 was granted to Astellas Pharma on Jul 6, 2022 following the initial filing on May 21, 2013 under the application number EP20163993A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BAYERApr 6, 2023ADMISSIBLE
MAIWALDApr 6, 2023ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents